Ra Medical Systems Stock

Ra Medical Systems EBIT/Assets

Delisted

The Operating Income to Assets Ratio (EBIT/Assets) of Ra Medical Systems (RMED) as of Aug 22, 2026 is -135.36 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -139.07 % — a change of -2.67% (higher).

EBIT/Assets

-135.36 %

YoY

-2.67%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Ra Medical Systems is 2026 -135.36 % . Operating Income to Assets Ratio (EBIT/Assets) of Ra Medical Systems was 2025 -139.07 % . It decreases by -2.67% higher compared to the previous year.
Access this data via the Eulerpool API

Ra Medical Systems Stock analysis

What does Ra Medical Systems do? Ra Medical Systems Inc. is a California-based company specializing in the development and sale of medical devices for the treatment of vascular diseases. The company was founded in 2002 and is headquartered in Carlsbad. The company was founded by Dr. Dean Irwin and Dr. Melissa Burstein, both experts in laser therapy. The company initially focused on developing laser systems for the treatment of skin diseases. In 2016, the company changed its business strategy and shifted its focus to the development of medical devices for the treatment of vascular diseases. Since then, the company has become a leading provider of devices for the treatment of peripheral artery occlusive disease (PAOD) and other vascular diseases. The business model of Ra Medical Systems Inc. is based on selling high-tech medical devices and their corresponding accessories. The company sells its products directly to medical facilities and healthcare providers in the US and some international markets. The company also provides training, technical support, and service to ensure the safe and effective use of its products. Ra Medical Systems Inc. offers two main products: the DABRA™ System and the Pharos™ System. Both systems use pulsed laser therapy for the treatment of vascular diseases. The DABRA™ System is a laser system specifically designed for the treatment of peripheral artery occlusive disease (PAOD). It is the only FDA-approved system that offers atherectomy laser therapy. The system enables fast and safe treatment of blocked arteries and is less invasive than traditional surgical procedures. The DABRA™ System also has the potential to reduce the need for long-term medication and repeated procedures, which can lower treatment costs. The Pharos™ System is a laser system specifically designed for the treatment of skin diseases such as psoriasis, vitiligo, and atopic dermatitis. The system uses a high-energy dose to selectively destroy abnormal functioning tissue without affecting surrounding tissue. The Pharos™ System has the potential to improve the quality of life for patients with skin diseases and expand therapeutic options for this patient group. Ra Medical Systems Inc. also offers a complete accessory catalog for its products, including catheters and accessories for the DABRA™ System and handpieces and cooling devices for the Pharos™ System. In conclusion, Ra Medical Systems Inc. is a leading provider of medical devices for the treatment of vascular diseases and skin diseases. The company specializes in the development of high-tech laser systems that provide safe and effective procedures for patients and doctors. The DABRA™ System is a revolutionary laser system for the treatment of PAOD that has the potential to reduce the need for invasive surgical procedures and long-term medication. The Pharos™ System expands therapeutic options for patients with skin diseases and has the potential to improve the quality of life for this patient group. Ra Medical Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ra Medical Systems stock

Operating Income to Assets Ratio (EBIT/Assets) of Ra Medical Systems is -135.36 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Ra Medical Systems changed from -139.07 % to -135.36 %, representing a -2.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Ra Medical Systems since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Ra Medical Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Ra Medical Systems

All Key Metrics — Ra Medical Systems